Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Brett Giroir’s tenure as acting commissioner of the US FDA won’t last long, but it has marked another high water mark in the pro-innovation climate at the agency, which is an important message about what FDA commissioners do – and don’t – actually do.
US FDA sets 22 April for advisory committee review of obeticholic acid in NASH, though whether the extended review was due to scheduling issues or any questions about Intercept's application itself remain unclear.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.